Author Interviews, Clots - Coagulation, NEJM, Thromboembolism / 02.04.2019
Does Intermittent Leg Compression Reduce Blood Clots or Pulmonary Embolism?
MedicalResearch.com Interview with:
[caption id="attachment_48324" align="alignleft" width="128"]
Dr. Arabi[/caption]
Yaseen M. Arabi, M.D
Intensive Care Department
Ministry of National Guard Health Affairs
Riyadh, Saudi Arabia
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, is a complication of critical illness. Studies have demonstrated that despite pharmacologic thromboprophylaxis with unfractionated heparin or low-molecular weight heparin, 5-20% of critically ill patients develop deep vein thrombosis (DVT). The PREVENT trial evaluated whether adjunctive intermittent pneumatic compression reduces incident proximal lower limb DVT as detected on twice-weekly lower limb ultrasonography in critically ill patients receiving pharmacologic thromboprophylaxis with unfractionated heparin or low-molecular-weight heparin.
The trial was conducted in 20 sites in Saudi Arabia, Canada, Australia and India and included 2003 patients.
The trial found no difference in the primary end point of proximal leg DVT. The addition of intermittent pneumatic compression to pharmacologic thromboprophylaxis did not result in a lower incidence of pulmonary embolism or a composite outcome of venous thromboembolism or death from any cause at 28 days when compared to pharmacologic thromboprophylaxis alone.
Dr. Arabi[/caption]
Yaseen M. Arabi, M.D
Intensive Care Department
Ministry of National Guard Health Affairs
Riyadh, Saudi Arabia
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, is a complication of critical illness. Studies have demonstrated that despite pharmacologic thromboprophylaxis with unfractionated heparin or low-molecular weight heparin, 5-20% of critically ill patients develop deep vein thrombosis (DVT). The PREVENT trial evaluated whether adjunctive intermittent pneumatic compression reduces incident proximal lower limb DVT as detected on twice-weekly lower limb ultrasonography in critically ill patients receiving pharmacologic thromboprophylaxis with unfractionated heparin or low-molecular-weight heparin.
The trial was conducted in 20 sites in Saudi Arabia, Canada, Australia and India and included 2003 patients.
The trial found no difference in the primary end point of proximal leg DVT. The addition of intermittent pneumatic compression to pharmacologic thromboprophylaxis did not result in a lower incidence of pulmonary embolism or a composite outcome of venous thromboembolism or death from any cause at 28 days when compared to pharmacologic thromboprophylaxis alone.
Dr. Landoni[/caption]
Dr. Giovanni Landoni
Intensive Care and Anesthesia Unit
Associate professor
Università Vita-Salute San Raffaele
MedicalResearch.com: What is the background for this study?
Response: Patients undergoing cardiac surgery are still at risk for perioperative complications. Studies to improve clinical outcomes this setting are important. Inhaled anesthetics have pharmacological properties which reduce myocardial infarction size by 50% in laboratory and animal studies and which might decrease postoperative mortality according to aggregated published randomized data.
Dr. Zhu[/caption]
Wenjia Zhu, PhD.
Marshall J. Seidman Fellow
Department of Health Care Policy
Harvard Medical School
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The current opioid epidemic continues to cause deaths and tremendous suffering in the United States, driven in large part by overuse of prescription opioids. Of special concern are new opioid prescriptions, i.e. opioids given to patients who have not used opioids before, which research tells us are an important gateway to long-term opioid use, misuse, overdoes and death. Recently, in their efforts to curb over prescribing of opioids, the CDC issued guidelines (December 2015 in draft form; March 2016 in final version) to encourage opioid prescribers to limit the use, duration and dose of opioids, particularly opioids to first-time users. Despite these, little is known about the prescribing of opioids to first-time users on a national scale, particularly among commercially insured patients.
In this study, we examined national monthly trends in the rate at which opioid therapy was started among commercially insured patients. Using administrative claims from Blue Cross Blue Shield Association commercial insurers from 2012 to 2017, we analyzed more than 86 million commercially insured patients across the United States.
Dr. Callaghan[/caption]
Dr. Miech[/caption]
Richard Miech Ph.D
Professor
Principal Investigator, Monitoring the Future
Institute for Social Research
University of Michigan
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Every year Monitoring the Future conducts a survey to examine trends in adolescent substance use. We draw a random sample of schools from a list of all schools in the United States and conduct our survey in ~400 schools. Our survey is representative of U.S. 8th, 10th, and 12th grade students. In other words, our results are what you would find if you surveyed every single 8th, 10th, and 12th graders in the United States, within the bounds of a small sampling error of a few percentage points.
An increase in vaping is the big news for 2018. In 10th and 12th grade the increase in nicotine vaping was the largest we've ever seen for any substance in the past 43 years. As a result of this increase in nicotine vaping, overall use of nicotine increased as well, which suggests that vaping is drawing youth into nicotine use. We also saw a significant increase in marijuana vaping.
